Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer.

ABSTRACT: Epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) was first recognized in 2004 as a distinct, clinically relevant molecular subset of lung cancer. The disease has been the subject of intensive research at both the basic scientific and clinical levels, becoming a paradigm for how to understand and treat oncogene-driven carcinomas. Although patients with EGFR-mutant tumours have increased sensitivity to tyrosine kinase inhibitors (TKIs), primary and acquired resistance to these agents remains a major clinical problem. This Review summarizes recent developments aimed at treating and ultimately curing the disease.

SUBMITTER: Pao W 

PROVIDER: S-EPMC3072803 | biostudies-literature | 2010 Nov

REPOSITORIES: biostudies-literature